Jasper Therapeutics
JSPR
23 hedge funds and large institutions have $15.7M invested in Jasper Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
0.1% more ownership
Funds ownership: 5.45% → 5.54% (+0.1%)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
58% less capital invested
Capital invested by funds: $37.5M → $15.7M (-$21.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Fernwood Investment Management
Quincy,
Massachusetts
|
+$544K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$334K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$236K |
| 4 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$156K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$577K |
| 2 |
BC
BIT Capital
Berlin,
Germany
|
-$57.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$32K |
| 4 |
Goldman Sachs
New York
|
-$20K |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
-$12K |
JSPR Hedge Fund Activity: Q3 2022 in Review
23 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2022, worth a combined $15.7M — down 58% from $37.5M a quarter earlier.
Fund positioning in JSPR was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 3 trimmed.
The largest buyer was Fernwood Investment Management, opening a new position worth an estimated $544K. The largest seller was Sectoral Asset Management, cutting an estimated $577K.
- 23 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $15.7M of Jasper Therapeutics stock for Q3 2022, down 58% quarter-over-quarter.
- 5 funds opened new Jasper Therapeutics positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest Jasper Therapeutics buyer in Q3 2022 was Fernwood Investment Management, an estimated $544K added.
- The largest Jasper Therapeutics seller in Q3 2022 was Sectoral Asset Management, an estimated $577K sold.
Based on aggregated 13F filings for Q3 2022.